Demand for improved pharmaceutical care that enhances the patient experience is ever increasing, and meanwhile outcomes-based medicine has become a key focus for health authorities around the world
Having clear parameters of patient‑centricity that can be measured year-on-year enables Boehringer Ingelheim UK to know if it is moving in the right direction and to set targets for what it hop
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.